Incontinence & Overactive Bladder Health Center
Study: Female Incontinence Is Common
Feb. 29, 2008 -- Women often don't tell their doctors about incontinence, overactive bladder, and pelvic organ prolapse, but those problems are common, a new study shows.
The study urges women not to accept those problems as a normal part of aging.
"Rather, they should focus on modifiable risk factors such as weight loss and maintenance, and seek treatment for all conditions when they occur," the researchers write in the March edition of Obstetrics & Gynecology.
The study included 4,103 women aged 25 to 84 (average age: 56) who got their health care through Kaiser Permanente Southern California.
The women completed surveys about the following pelvic floor disorders:
- Stress urinary incontinence: urine leakage when there is an increase in abdominal pressure, such as while exercising, laughing, sneezing, or coughing.
- Overactive bladder: an urgent need to urinate.
- Pelvic organ prolapse: the descent or drooping of the bladder, uterus, vagina, small bowel, or rectum.
- Anal incontinence: defined in the study as leaking gas, as well as solid or liquid stool.
The survey's results:
- 15% reported stress urinary incontinence
- 13% reported overactive bladder
- 6% reported pelvic organ prolapse
- 25% reported anal incontinence
Many women had more than one pelvic floor disorder.
"Roughly 80% of women with stress urinary incontinence or overactive bladder, 69% with pelvic organ prolapse, and 48% with anal incontinence reported at least one other [pelvic floor] disorder," write the researchers, who included Jean Lawrence, ScD, MPH, of Kaiser Permanente Southern California.
Pelvic floor disorders were more common among older women. But age wasn't as important as other factors, such as the number of babies the women had had by vaginal birth, menopause, hysterectomy, smoking, and obesity.
It's not clear if the results apply to all women. Those with pelvic floor disorders may have been more likely than women without those problems to complete the survey.
Indication
Uroxatral® (alfuzosin HCl 10 mg extended-release tablets) is an alpha1-blocker for the treatment of the signs and symptoms of BPH.
Important Safety Information
Do not take UROXATRAL if you have liver problems or if you are taking antifungal drugs like ketoconazole or itraconazole, or HIV drugs like ritonavir.
UROXATRAL can cause a sudden drop in blood pressure, especially when starting treatment. This may lead to fainting, dizziness, and lightheadedness. Do not drive, operate machinery, or do any dangerous activity until you know how UROXATRAL will affect you. This is especially important if you already have a problem with low blood pressure or take medicines to treat high blood pressure. There may be an increased risk of low blood pressure and fainting when taking UROXATRAL in combination with blood pressure medication or nitrates, or erectile dysfunction medication.
If considering cataract surgery (clouding of the eyes), tell your eye surgeon that you are currently taking UROXATRAL or have previously been treated with an alpha-blocker.
Before taking UROXATRAL, tell your doctor if you have kidney problems.
Also, tell your doctor if you or any family member(s) have or take medications for a rare heart condition known as congenital prolongation of the QT interval.
BPH and prostate cancer can cause the same symptoms. However, UROXATRAL is not a treatment for prostate cancer.
The most common side effects with UROXATRAL are dizziness, upper respiratory tract infection, headache, and tiredness.
Please see UROXATRAL full prescribing information.



